NeoGenomics Gestione

Gestione criteri di controllo 3/4

NeoGenomics Il CEO è Chris Smith, nominato in Aug2022, e ha un mandato di 2.25 anni. la retribuzione annua totale è $ 11.67M, composta da 8.6% di stipendio e 91.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.5% delle azioni della società, per un valore di € 9.16M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2 anni e 3.8 anni.

Informazioni chiave

Chris Smith

Amministratore delegato

US$11.7m

Compenso totale

Percentuale dello stipendio del CEO	8.6%
Mandato del CEO	2.3yrs
Proprietà del CEO	0.5%
Durata media del management	2yrs
Durata media del Consiglio di amministrazione	3.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Chris Smith rispetto agli utili di NeoGenomics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$78m
Jun 30 2024	n/a	n/a	-US$79m
Mar 31 2024	n/a	n/a	-US$84m
Dec 31 2023	US$12m	US$1m	-US$88m
Sep 30 2023	n/a	n/a	-US$96m
Jun 30 2023	n/a	n/a	-US$115m
Mar 31 2023	n/a	n/a	-US$126m
Dec 31 2022	US$15m	US$346k	-US$144m

Compensazione vs Mercato: La retribuzione totale di Chris ($USD 11.67M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 1.62M ).

Compensazione vs guadagni: La retribuzione di Chris è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Chris Smith (61 yo)

2.3yrs

Mandato

US$11,665,946

Compensazione

Mr. Christopher Michael Smith, also known as Chris, serves as Chief Executive Officer at NeoGenomics Laboratories, Inc. since August 2022. He serves as Director at NeoGenomics Laboratories, Inc. since 2023...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Christopher Smith	CEO & Director	2.3yrs	US$11.67m	0.50% € 9.2m
Jeffrey Sherman	Chief Financial Officer	1.9yrs	US$3.55m	0.12% € 2.1m
Vishal Sikri	President of Advanced Diagnostics	2.8yrs	US$2.37m	0.10% € 1.8m
Melody Harris	President & COO of Informatics	1.9yrs	US$4.69m	0.084% € 1.5m
Warren Stone	Chief Commercial Officer	2yrs	US$3.01m	0.078% € 1.4m
Gregory Aunan	Chief Accounting Officer	1.5yrs	Nessun dato	0.011% € 204.8k
Kendra Sweeney	Vice President of Investor Relations & Communications	no data	Nessun dato	Nessun dato
Alicia Olivo	Executive VP of Business Development	2.6yrs	Nessun dato	0.033% € 597.0k
Hutan Hashemi	Chief Compliance Officer	2.6yrs	Nessun dato	Nessun dato
Derek Lyle	Chief Medical Officer	3.8yrs	Nessun dato	Nessun dato
Gary Passman	Chief Culture Officer	1.8yrs	Nessun dato	Nessun dato
Kareem Saad	Head of Strategy & Transformation	less than a year	Nessun dato	Nessun dato

2.0yrs

Durata media

51yo

Età media

Gestione esperta: Il team dirigenziale di NG9 è considerato esperto (durata media dell'incarico 2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Christopher Smith	CEO & Director	2.3yrs	US$11.67m	0.50% € 9.2m
Michael Kelly	Independent Director	4.3yrs	US$317.50k	0.025% € 449.9k
Lynn Tetrault	Independent Chair of the Board	9.4yrs	US$365.00k	0.048% € 869.7k
Bernard Fox	Member of Scientific Advisory Board	3.8yrs	Nessun dato	Nessun dato
Riccardo Dalla-Favera	Member of Scientific Advisory Board	3.8yrs	Nessun dato	Nessun dato
Anthony Zook	Independent Director	1.4yrs	US$276.23k	0.0088% € 160.6k
Steven Rosen	Member of Scientific Advisory Board	3.8yrs	Nessun dato	Nessun dato
James Downing	Member of Scientific Advisory Board	3.8yrs	Nessun dato	Nessun dato
Stephen Kanovsky	Independent Director	7.3yrs	US$309.20k	0.028% € 511.3k
Razelle Kurzrock	Member of Scientific Advisory Board	3.8yrs	Nessun dato	Nessun dato
Alison Hannah	Member of Scientific Advisory Board & Independent Director	9.4yrs	US$305.00k	0.093% € 1.7m
Mark Rubin	Member of Scientific Advisory Board	3.8yrs	Nessun dato	Nessun dato

3.8yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NG9 sono considerati esperti (durata media dell'incarico 3.8 anni).

NeoGenomics Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics

NeoGenomics, Inc., Annual General Meeting, May 23, 2024

NeoGenomics, Inc. Expands Board of Directors with Appointments of Three Independent Directors

Neogenomics, Inc. Announces Resignation of David J. Daly to Board of Directors

NeoGenomics, Inc. Announces Executive Changes

NeoGenomics, Inc. Appoints Melody Harris as President, Enterprise Operations effective December 5, 2022

Recent updates

Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.15 loss in 3Q 2023)

Neogenomics, Inc. Revises Full-Year 2024 Guidance

NeoGenomics, Inc. to Report Q3, 2024 Results on Nov 05, 2024

NeoGenomics, Inc. Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia

NeoGenomics, Inc. Revises Earnings Guidance for the Full-Year 2024

Second quarter 2024 earnings released: US$0.15 loss per share (vs US$0.19 loss in 2Q 2023)

NeoGenomics, Inc. to Report Q2, 2024 Results on Jul 29, 2024

NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO

NeoGenomics, Inc. Reaffirms Consolidated Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.25 loss in 1Q 2023)

NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics

NeoGenomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024

NeoGenomics, Inc., Annual General Meeting, May 23, 2024

Full year 2023 earnings released: US$0.70 loss per share (vs US$1.16 loss in FY 2022)

NeoGenomics, Inc. Provides Earnings Guidance for the Year 2024

NeoGenomics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

NeoGenomics Laboratories, Inc. to Appeal Ruling

NeoGenomics, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023

Third quarter 2023 earnings released: US$0.15 loss per share (vs US$0.30 loss in 3Q 2022)

Neogenomics, Inc. Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios

NeoGenomics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: US$0.19 loss per share (vs US$0.28 loss in 2Q 2022)

NeoGenomics, Inc. Expands Board of Directors with Appointments of Three Independent Directors

NeoGenomics, Inc.'s RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

NeoGenomics, Inc. and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

NeoGenomics, Inc. to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.25 loss per share (vs US$0.40 loss in 1Q 2022)

Full year 2022 earnings released: US$1.16 loss per share (vs US$0.07 loss in FY 2021)

NeoGenomics, Inc. Announces Results of a New Study of the RaDaR Assay in Patients with Muscle-Invasive Bladder Cancer

Neogenomics, Inc. Announces Resignation of David J. Daly to Board of Directors

The Klein Law Firm Announces Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Neogenomics, Inc. Shareholders

Gibbs Law Group Announces Files Class Action Lawsuit Against NeoGenomics Inc

NeoGenomics, Inc. Announces Executive Changes

Neogenomics, Inc. Announces Radar Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

NeoGenomics, Inc. Appoints Melody Harris as President, Enterprise Operations effective December 5, 2022

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.30 loss per share (vs US$0.17 loss in 3Q 2021)

NeoGenomics Appoints David Perez to its Board of Directors

NeoGenomics, Inc. Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch

NeoGenomics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$0.28 loss per share (vs US$0.64 profit in 2Q 2021)

NeoGenomics, Inc. Appoints Chris Smith as Chief Executive Officer, Effective August 15, 2022

NeoGenomics, Inc.(NasdaqCM:NEO) dropped from Russell 2000 Growth-Defensive Index

NeoGenomics, Inc. Announces Resignation of Douglas Brown as Chief Strategy and Corporate Development Officer

Neogenomics, Inc. Announces Executive Changes, Effective May 23, 2022

First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.19 loss in 1Q 2021)

High number of new and inexperienced directors

NeoGenomics, Inc., Annual General Meeting, Jun 02, 2022

NeoGenomics, Inc. Provides Revenue Guidance for the First Quarter 2022

NeoGenomics, Inc. Announces Management Changes

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Neogenomics, Inc. Provides Earnings Guidance for the Year 2022

Investor sentiment deteriorated over the past week

CEO & Director recently bought €462k worth of stock

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.023 profit in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS US$0.64 (vs US$0.063 loss in 2Q 2020)

High number of new and inexperienced directors

President of Pharma Services Division recently sold €6.7m worth of stock

Independent Director Raymond Hipp has left the company

Director Steven Jones has left the company

President of Clinical Services Division recently sold €117k worth of stock

Chief Medical Officer has left the company

First quarter 2021 earnings released: US$0.19 loss per share (vs US$0.067 loss in 1Q 2020)

NeoGenomics, Inc. Announces Chief Executive Officer Changes

Full year 2020 earnings released: EPS US$0.038 (vs US$0.08 in FY 2019)